Jefferson Wang has been appointed as General Manager of Lotus Pharmaceutical, effective 1 September 2016. He succeeds Lotus CEO and General Manager Siegfried Gschliesser, who has had important role in building regional success of Lotus and Alvogen and decided to leave the company from his leadership role. As such, the CEO role at Lotus will be closed and Jefferson will continue to oversee the domestic market in Taiwan.
Commenting on the appointment, Petar Vazharov, Board Director at Lotus, said: “Jefferson is a very strong appointment and has all the necessary credentials to drive Lotus domestic business in Taiwan forward through the next exciting stage of its development. Since its merger with Alvogen in the APAC region in 2014, Lotus has made impressive progress by more than five folding its regional annual revenue and significantly expanding its product portfolio, pipeline and regional coverage. Its regional footprint now covers 11 APAC markets, including Korea, Japan, China and Thailand. I am confident that, with Jefferson at the helm, Lotus is very well positioned to achieve its vision of becoming one of the leading pharmaceutical companies in Taiwan.”